Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 2, 1999, Pages 118-127

  Lilja, Jari J ^b   Kivistö, Kari T ^b   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CITRUS FRUIT EXTRACT; PRAVASTATIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; ENZYME REGULATION; FEMALE; FIRST PASS EFFECT; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; INTESTINE ABSORPTION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0242645646     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0009-9236(99)90048-6     Document Type: Article

References (24)

1. 1. Bailey DG, Arnold JMO, Munoz C, Spence JD. Grapefruit-felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther 1993;53: 637-42.
2. 2. Bailey DG, Arnold JMO, Strong HA, Munoz C, Spence JD. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther 1993;54:589-94.
3. 3. Yee GC, Stanley DL, Pessa LJ, Costa TD, Beltz SE, Ruiz J, et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995;345:955-6.
4. 4. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995;57:485-91.
5. 5. Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krähenbühl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995;58:20-8.
6. 6. Kantola T, Kivistö KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998;63:397-402.
7. 7. Lilja JJ, Kivistö KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998;64:477-83.
8. 8. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99:2545-53.
9. 9. Lea AP, McTavish D. Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 1997;53:828-47.
10. 10. Haria M, McTavish D. Pravastatin: a reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs 1997; 53:299-336.
11. 11. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, et al. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 1999;27:173-9.
12. 12. Horn M. Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals [letter]. Arch Dermatol 1996; 132:1254.
13. 13. Meier C, Stey B, Brack T, Maggiorini M, Risti B, Krähenbühl S. Rhabdomyolysis in patients treated with simvastatin and cyclosporin: role of the hepatic cytochrome P450 enzyme system. Schweiz Med Wochenschr 1995; 125:1342-6.
14. 14. Wong PWK, Dillard TA, Kroenke K. Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy. South Med J 1998;91:202-5.
15. 15. Kantola T, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998;64:58-65.
16. 16. Manning JA, Swanson BN, Emaus NA, Fry J. A semi-automated, radioenzymatic assay for pravastatin and lovastatin in human serum [abstract]. Pharm Res 1989; 6:S237.
17. 17. Yang BB, Siedlik PH, Smithers JA, Sedman JA, Stern RH. Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates: erythromycin and ethinyl estradiol [abstract]. Pharm Res 1996;13:S437.
18. 18. Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-41.
19. 19. Donahue S, Chen L, Wason J, Norton J, Franc J. Effect of erythromycin on the pharmacokinetics of pravastatin and simvastatin [abstract]. Seventieth Congress of the European Atherosclerosis Society, Geneva, Switzerland; 1998. p. 50.
20. 20. Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998;64:369-77.
21. 21. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60:54-61.
22. 22. Bailey DG, Arnold JMO, Bend JR, Tran LT, Spence JD. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br J Clin Pharmacol 1995;40:135-40.
23. 23. Takanaga H, Ohnihsi A, Matsuo H, Sawada Y. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol Pharm Bull 1998;21:1062-6.
24. 24. Kitazawa E, Tamura N, Iwabuchi H, Uchiyama M, Muramatsu S, Takahagi H, et al. Biotransformation of pravastatin sodium; I: mechanism of enzymic transformation of epimerization of an allylic hydroxy group of pravastatin sodium. Biochem Biophys Res Commun 1993;192:597-602.